Ionis Pharmaceuticals IONS IONISAZ625 — Revenue
Discontinued — last reported Q1 '18
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ionis Pharmaceuticals’s 10-K, filed March 1, 2019, on SEC EDGAR. View the filing →
Questions, answered.
- What does IONISAZ625 — revenue mean?
- The total sales revenue generated from a specific product or service segment, excluding taxes.
- How do you interpret IONISAZ625 — revenue?
- An increase indicates growing market demand, successful commercialization, or expanded licensing activity for this specific segment, while a decrease may signal market saturation, competitive pressure, or the expiration of key contracts.
- How does IONISAZ625 — revenue compare across companies?
- Comparable to product-specific revenue lines or segment-level net sales reported by other biotechnology and pharmaceutical firms engaged in drug discovery and commercialization.